We use cosmetics every day without giving it much thought. We trust that if they are on the market, they have passed sufficient checks. But few realize that these controls are not designed to detect hormonal alterations, nor to evaluate real and continuous exposure. That is where the problems with endocrine disruptors begin.
🚫 Why toxicological regulations in cosmetics are not enough to regulate endocrine disruptors
For decades, the safety of cosmetic products has been evaluated using the principles of classical toxicology. This approach has been useful for identifying clearly toxic substances and preventing obvious health risks. However, when we talk about endocrine disruptors, this model begins to show significant limitations.
Science has been warning for years that endocrine disruptors do not behave like traditional toxins. And yet, we continue to try to regulate them with tools designed for other types of risks. The result is a false sense of security.
Why does this happen?
1. Because classical toxicology does not explain how endocrine disruptors act
Traditional toxicology is based on a well-known idea: the dose makes the poison. According to this principle, a substance is only dangerous when a certain amount is exceeded, and below that threshold, it can be considered safe.
The problem is that this reasoning does not work for the hormonal system.
Hormones act at extremely low doses. Our body is designed to respond to minimal signals, not large amounts. Therefore, a substance does not need to be toxic to have a relevant effect: it is enough for it to mimic, block, or alter a hormonal signal.
Endocrine disruptors work precisely like this. They do not damage tissues or cause immediate toxicity. They act as false signals that confuse the body. In fact, many studies have shown that these substances can produce effects at very low doses, even lower than those used in regulatory tests, and that their response does not always increase with the dose. In some cases, low doses are the most active.
This makes classic safety parameters, such as the NOAEL or safety margins, of little use in this context. These values are calculated by looking for visible effects at high doses, but endocrine effects can appear much earlier, without the evaluation system detecting them.
For this reason, a substance can meet all legal requirements and still interfere with the hormonal system under real-world conditions of use. It is not a problem of lack of data, but of using a model that does not fit the mechanism of action. Classical toxicology looks for damage; endocrine disruptors reprogram.
2. Because the timing of exposure is not taken into account

Another major blind spot in cosmetic regulation is that it does not consider when exposure occurs. Safety tests almost always focus on healthy adults and short- or medium-term effects. This may be useful for detecting irritation or general toxicity, but not for evaluating endocrine risks.
The hormonal system is not equally sensitive throughout life. There are key stages—pregnancy, fetal development, childhood, and puberty—in which hormones not only regulate functions but also direct the development of the organism. During these critical windows, small alterations can have permanent consequences.
A substance that produces no visible effect in an adult can irreversibly alter hormonal development if exposure occurs during gestation or childhood. In these cases, the effect does not appear immediately. It may manifest years later, when it is no longer easy to relate it to the original exposure.
Current cosmetic regulations do not evaluate these types of risks. They do not contemplate prenatal exposures, they do not differentiate vulnerability based on the life stage, and they do not require specific studies on endocrine development. As a result, many potentially relevant effects are simply not looked for.
3. Because long-term and transgenerational effects are ignored
Toxicological evaluation in cosmetics is designed to detect relatively rapid and measurable effects. If a substance does not cause visible damage in the short or medium term, it is considered safe.
However, endocrine disruptors do not always act this way.
Hormonal interference can initiate biological processes that remain silent for years and only manifest later, in the form of reproductive problems, thyroid alterations, metabolic disorders, or other hormone-dependent diseases. There is an increasing number of studies linking early exposures to pathologies that appear in adulthood.
Furthermore, many endocrine disruptors can cause epigenetic changes, that is, modifications in how genes are expressed without altering the DNA. These changes can accompany a person throughout their life and, in some cases, even be passed on to future generations.
These types of effects are completely outside the current evaluation framework. Regulatory tests are not designed to observe long-term consequences or to analyze potential impacts on offspring. The regulatory model falls short when the damage is not immediate.

4. Because isolated substances are evaluated, not actual exposure
In cosmetic regulations, each ingredient is evaluated individually. If a substance, by itself, is below its "safe" limit, it is considered that there is no risk.
But this situation does not reflect reality.
In daily life, we use several cosmetic products per day: gel, shampoo, cream, deodorant, makeup… Each contains multiple ingredients. Actual exposure is simultaneous and cumulative, not isolated.
When several substances with hormonal activity act at the same time, they can add up or enhance their effects, even if each one is below its individual limit. This phenomenon, known as the cocktail effect, is well documented scientifically, but is barely taken into account in cosmetic regulation.
The current framework does not evaluate combined exposure, nor does it consider that several endocrine disruptors may act on the same hormonal systems. Consequently, the real risk may be very different from what regulatory studies describe.
Conclusion: the problem is not the lack of rules, but the approach
These four points make it clear that the problem lies not in the absence of tests or poor enforcement of regulations, but in the conceptual model on which it is based. Classical toxicology is not designed to detect hormonal interference at low doses, does not consider the timing of exposure, ignores effects that appear years later, and evaluates substances in isolation, far from real-world exposure.
Applying this approach to endocrine disruptors inevitably means underestimating the risk. As long as cosmetic regulation does not incorporate advances in endocrinology and a more realistic view of how we are exposed to these substances, there will continue to be a gap between the theoretical safety set by regulations and the actual protection of health in the long term.